Molecular and Cellular Biochemistry

, Volume 425, Issue 1–2, pp 85–93 | Cite as

Receptor-mediated toxicity of human amylin fragment aggregated by short- and long-term incubations with copper ions

  • Giuseppe Caruso
  • Donatella A. Distefano
  • Paolo Parlascino
  • Claudia G. Fresta
  • Giuseppe Lazzarino
  • Susan M. Lunte
  • Vincenzo G. Nicoletti
Article

Abstract

Human amylin (hA1–37) is a polypeptide hormone secreted in conjunction with insulin from the pancreatic β-cells involved in the pathogenesis of type 2 diabetes mellitus (T2DM). The shorter fragment hA17–29 than full-length peptide is capable to form amyloids "in vitro". Here, we monitored the time course of hA17–29 β-amyloid fibril and oligomer formation [without and with copper(II)], cellular toxicity of different amyloid aggregates, and involvement of specific receptors (receptor for advanced glycation end-products, RAGE; low-affinity nerve growth factor receptor, p75-NGFR) in aggregate toxicity. Fibril and oligomer formation of hA17–29 incubated at 37 °C for 0, 48, and 120 h, without or with copper(II), were measured by the thioflavin T fluorescence assay and ELISA, respectively. Toxicity of hA17–29 aggregates and effects of anti-RAGE and anti-p75-NGFR antibodies were evaluated on neuroblastoma SH-SY5Y viability. Fluorescence assay of hA17–29 indicates an initial slow rate of soluble fibril formation (48 h), followed by a slower rate of insoluble aggregate formation (120 h). The highest quantity of oligomers was recorded when hA17–29 was pre-aggregated for 48 h in the presence of copper(II) showing also the maximal cell toxicity (−44% of cell viability, p < 0.01 compared to controls). Anti-RAGE or anti-p75-NGFR antibodies almost abolished cell toxicity of hA17–29 aggregates. These results indicate that copper(II) influences the aggregation process and hA17–29 toxicities are especially attributable to oligomeric aggregates. hA17–29 aggregate toxicity seems to be mediated by RAGE and p75-NGFR receptors which might be potential targets for new drugs in T2DM treatment.

Keywords

Aggregation Amylin Oligomers Cell viability Copper Receptor-mediated cell toxicity 

Supplementary material

11010_2016_2864_MOESM1_ESM.doc (322 kb)
Supplementary material 1 (DOC 322 kb)

References

  1. 1.
    Carrell RW, Lomas DA (1997) Conformational disease. Lancet 350:134–138CrossRefPubMedGoogle Scholar
  2. 2.
    Kelly JW (1996) Alternative conformations of amyloidogenic proteins govern their behavior. Curr Opin Struct Biol 6:11–17CrossRefPubMedGoogle Scholar
  3. 3.
    Gaggelli E, Kozlowski H, Valensin D, Valensin G (2006) Copper homeostasis and neurodegenerative disorders (Alzheimer’s, prion, and Parkinson’s diseases and amyotrophic lateral sclerosis). Chem Rev 106:1995–2044CrossRefPubMedGoogle Scholar
  4. 4.
    Prager R, Ludvik B, Hartter E (1991) Role of amylin in the pathogenesis of type II diabetes mellitus. Acta Med Austriaca 18:61–62PubMedGoogle Scholar
  5. 5.
    Jaikaran S, Clark A (2001) Islet amyloid and type 2 diabetes: from molecular misfolding to islet pathophysiology. Biochim Biophys Acta 1537:179–203CrossRefPubMedGoogle Scholar
  6. 6.
    Kodali R, Wetzel R (2007) Polymorphism in the intermediates and products of amyloid assembly. Curr Opin Struc Biol 17:48–57CrossRefGoogle Scholar
  7. 7.
    Tatarek-Nossol M, Yan LM, Schmauder A, Tenidis K, Westermark G, Kapurniotu A (2005) Inhibition of hIAPP amyloid-fibril formation and apoptotic cell death by a designed hIAPP amyloid-core-containing hexapeptide. Chem Biol 12:797–809CrossRefPubMedGoogle Scholar
  8. 8.
    Zhao J, Yu X, Liang G, Zheng J (2011) Structural polymorphism of human islet amyloid polypeptide (hIAPP) oligomers highlights the importance of interfacial residue interactions. Biomacromolecules 12:210–220CrossRefPubMedGoogle Scholar
  9. 9.
    Tenidis K, Waldner M, Bernhagen J, Fischle W, Bergmann M, Weber M, Merkle ML, Voelter ML, Brunner H, Kapurniotu A (2000) Identification of a penta- and hexapeptide of islet amyloid polypeptide (IAPP) with amyloidogenic and cytotoxic properties. J Mol Biol 295:1055–1071CrossRefPubMedGoogle Scholar
  10. 10.
    Pappalardo G, Milardi D, Magrì A, Attanasio F, Impellizzeri G, La Rosa C, Grasso D, Rizzarelli E (2007) Environmental factors differently affect human and rat IAPP: conformational preferences and membrane interactions of IAPP17-29 peptide derivatives. Chemistry 13:10204–10215CrossRefPubMedGoogle Scholar
  11. 11.
    Mazzaglia A, Micali N, Scolaro LM, Attanasio F, Magrí A, Pappalardo G, Villari V (2010) Aggregation properties of the peptide fragments derived from the 17 to 29 region of the human and rat IAPP: a comparative study with two PEG-conjugated variants of the human sequence. J Phys Chem B 114:705–713CrossRefPubMedGoogle Scholar
  12. 12.
    Noy D, Solomonov I, Sinkevich O, Arad T, Kjaer K, Sagi I (2008) Zinc-amyloid beta interactions on a millisecond time-scale stabilize non-fibrillar Alzheimer-related species. J Am Chem Soc 130:1376–1383CrossRefPubMedGoogle Scholar
  13. 13.
    Ridge PG, Zhang Y, Gladyshev VN (2008) Comparative genomic analyses of copper transporters and cupro proteomes reveal evolutionary dynamics of copper utilization and its link to oxygen. PLoS ONE 3:e1378CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Ward B, Walker K, Exley C (2008) Copper(II) inhibits the formation of amylin amyloid in vitro. J Inorg Biochem 102:371–375CrossRefPubMedGoogle Scholar
  15. 15.
    Mold M, Bunrat C, Goswami P, Roberts A, Roberts C, Taylor N, Taylor H, Wu L, Fraser PE, Exley C (2015) Further insight into the role of metals in amyloid formation by IAPP1-37 and ProIAPP1-48. J Diab Res Clin Met 4:4CrossRefGoogle Scholar
  16. 16.
    Exley C, Mold M, Shardlow E, Shuker B, Ikpe B, Wu L, Fraser PE (2012) Copper is a potent inhibitor of the propensity for human ProIAPP1-48 to form amyloid fibrils in vitro. J Diabetes Res Clin Metab 1:3CrossRefGoogle Scholar
  17. 17.
    Masad A, Hayes L, Tabner BJ, Turnbull S, Cooper LJ, Fullwood NJ, German MJ, Kametani F, El-Agnaf OMA, Allsop D (2007) Copper mediated formation of hydrogen peroxide from the amylin peptide: a novel mechanism for degeneration of islet cells in type-2 diabetes mellitus? FEBS Lett 581:3489–3493CrossRefPubMedGoogle Scholar
  18. 18.
    Yu YP, Lei P, Hu J, Wu WH, Zhao YF, Li YM (2010) Copper-induced cytotoxicity: reactive oxygen species or islet amyloid polypeptide oligomer formation. Chem Commun 46:6909–6911CrossRefGoogle Scholar
  19. 19.
    Tabner BJ, El-Agnaf OMA, German MJ, Fullwood NJ, Allsop D (2005) Protein aggregation, metals and oxidative stress in neurodegenerative diseases. Biochem Soc Trans 33:1082–1086CrossRefPubMedGoogle Scholar
  20. 20.
    Yamagishi S, Takeuchi M, Inagaki Y, Nakamura K, Imaizumi T (2003) Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy. Int J Clin Pharmacol Res 23:129–134PubMedGoogle Scholar
  21. 21.
    Ramasamy R, Yan SF, Schmidt AM (2011) Receptor for AGE (RAGE): signalling mechanisms in the pathogenesis of diabetes and its complications. Ann N Y Acad Sci 1243:88–102CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Bucciarelli LG, Wendt T, Rong L, Lalla E, Hofmann MA, Goova MT, Taguchi A, Yan SF, Yan SD, Stern DM, Schmidt AM (2002) RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell Mol Life Sci 59:1117–1128CrossRefPubMedGoogle Scholar
  23. 23.
    Gong W, Liu ZH, Zeng CH, Peng A, Chen HP, Zhou H, Li LS (2007) Amylin deposition in the kidney of patients with diabetic nephropathy. Kidney Int 72:213–218CrossRefPubMedGoogle Scholar
  24. 24.
    Davies AM (2003) Regulation of neuronal survival and death by extracellular signals during development. EMBO J 22:2537–2545CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Jackson K, Barisone GA, Diaz E, Jin LW, DeCarli C, Despa F (2013) Amylin deposition in the brain: a second amyloid in Alzheimer disease? Ann Neurol 74:517–526CrossRefPubMedGoogle Scholar
  26. 26.
    Srodulski S, Sharma S, Bachstetter AB, Brelsfoard JM, Pascual C, Xie XS, Saatman KE, Van Eldik LJ, Despa F (2014) Neuroinflammation and neurologic deficits in diabetes linked to brain accumulation of amylin. Mol Neurodegener 9:30CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Khurana R, Coleman C, Ionescu-Zanetti C, Carter SA, Krishna V, Grover RK, Roy R, Singh S (2005) Mechanism of thioflavin T binding to amyloid fibrils. J Struct Biol 151:229–238CrossRefPubMedGoogle Scholar
  28. 28.
    Ono K, Condron MM, Teplow DB (2009) Structure-neurotoxicity relationships of amyloid beta-protein oligomers. Proc Natl Acad Sci USA 106:14745–14750CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    LeVine H 3rd (1993) Thioflavine T interaction with synthetic Alzheimer’s disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci 2:404–410CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Wang X, Yu S, Wang CY, Wang Y, Liu HX, Cui Y, Zhang LD (2015) Advanced glycation end products induce oxidative stress and mitochondrial dysfunction in SH-SY5Y cells. In Vitro Cell Dev Biol Anim 51:204–209CrossRefPubMedGoogle Scholar
  31. 31.
    Holik AK, Rohm B, Somoza MM, Somoza V (2013) N(ε)-Carboxymethyllysine (CML), a Maillard reaction product, stimulates serotonin release and activates the receptor for advanced glycation end products (RAGE) in SH-SY5Y cells. Food Funct 4:1111–1120CrossRefPubMedGoogle Scholar
  32. 32.
    Chakravarthy B, Gaudet C, Ménard M, Atkinson T, Brown L, Laferla FM, Armato U, Whitfield J (2010) Amyloid-beta peptides stimulate the expression of the p75(NTR) neurotrophin receptor in SHSY5Y human neuroblastoma cells and AD transgenic mice. J Alzheimers Dis 19:915–925PubMedGoogle Scholar
  33. 33.
    Giraud S, Lautrette C, Bessette B, Decourt C, Mathonnet M, Jauberteau MO (2005) Modulation of Fas-induced apoptosis by p75 neurotrophin receptor in a human neuroblastoma cell line. Apoptosis 10:1271–1283CrossRefPubMedGoogle Scholar
  34. 34.
    Götz J, Lim YA, Eckert A (2013) Lessons from two prevalent amyloidoses—what amylin and Aβ have in common. Front Aging Neurosci 5:38CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Fu W, Patel A, Jhamandas JH (2013) Amylin receptor: a common pathophysiological target in Alzheimer’s disease and diabetes mellitus. Front Aging Neurosci 5:42CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Jhamandas JH, Li Z, Westaway D, Yang J, Jassar S, MacTavish D (2011) Actions of β-amyloid protein on human neurons are expressed through the amylin receptor. Am J Pathol 178:140–149CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Finder VH, Glockshuber R (2007) Amyloid-beta aggregation. Neurodegener Dis 4:13–27CrossRefPubMedGoogle Scholar
  38. 38.
    House E, Collingwood J, Khan A, Korchazkina O, Berthon G, Exley C (2004) Aluminium, iron, zinc and copper influence the in vitro formation of amyloid fibrils of Abeta42 in a manner which may have consequences for metal chelation therapy in Alzheimer’s disease. J Alzheimers Dis 6:291–301PubMedGoogle Scholar
  39. 39.
    Keskitalo S, Farkas M, Hanenberg M, Szodorai A, Kulic L, Semmler A, Weller M, Nitsch RM, Linnebank M (2014) Reciprocal modulation of Aβ42 aggregation by copper and homocysteine. Front Aging Neurosci 6:237. doi:10.3389/fnagi.2014.00237 CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Bin Y, Li X, He Y, Chen S, Xiang J (2013) Amyloid-β peptide (1-42) aggregation induced by copper ions under acidic conditions. Acta Biochim Biophys Sin (Shanghai) 45:570–577CrossRefGoogle Scholar
  41. 41.
    Giuffrida ML, Grasso G, Ruvo M, Pedone C, Saporito A, Marasco D, Pignataro B, Cascio C, Copani A, Rizzarelli E (2007) Abeta(25-35) and its C- and/or N-blocked derivatives: copper driven structural features and neurotoxicity. J Neurosci Res 85:623–633CrossRefPubMedGoogle Scholar
  42. 42.
    House E, Mold M, Collingwood J, Baldwin A, Goodwin S, Exley C (2009) Copper abolishes the beta-sheet secondary structure of preformed amyloid fibrils of amyloid-beta(42). J Alzheimers Dis 18:811–817PubMedPubMedCentralGoogle Scholar
  43. 43.
    Kandimalla R, Thirumala V, Reddy PH (2016) Is Alzheimer’s disease a type 3 diabetes? A critical appraisal. Biochim Biophys Acta (in press)Google Scholar
  44. 44.
    Rosales-Corral S, Tan DX, Manchester L, Reiter RJ (2015) Diabetes and Alzheimer disease, two overlapping pathologies with the same background: oxidative stress. Oxid Med Cell Longev 2015:985845CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Despa F, Decarli C (2013) Amylin: what might be its role in Alzheimer’s disease and how could this affect therapy? Expert Rev Proteomics 10:403–405CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Sims-Robinson C, Kim B, Rosko A, Feldman EL (2010) How does diabetes accelerate Alzheimer disease pathology? Nat Rev Neurol 6:551–559CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Carlsson CM (2010) Type 2 diabetes mellitus, dyslipidemia, and Alzheimer’s disease. J Alzheimers Dis 20:711–722PubMedPubMedCentralGoogle Scholar
  48. 48.
    Sridhar GR, Lakshmi G, Nagamani G (2015) Emerging links between type 2 diabetes and Alzheimer’s disease. World J Diabetes 6:744–751CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Kimura N (2016) Diabetes mellitus induces Alzheimer’s disease pathology: histopathological evidence from animal models. Int J Mol Sci 17:503CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Li X, Song D, Leng SX (2015) Link between type 2 diabetes and Alzheimer’s disease: from epidemiology to mechanism and treatment. Clin Interv Aging 10:549–560CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Walsh DM, Hartley DM, Kusumoto Y, Fezoui Y, Condron MM, Lomakin A, Benedek GB, Selkoe DJ, Teplow DB (1999) Amyloid β protein fibrillogenesis: structure and biological activity of protofibrillar intermediates. J Biol Chem 274:25945–25952CrossRefPubMedGoogle Scholar
  52. 52.
    Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL (1998) Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95:6448–6453CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Cassagnes LE, Hervé V, Nepveu F, Hureau C, Faller P, Collin F (2013) The catalytically active copper-amyloid-Beta state: coordination site responsible for reactive oxygen species production. Angew Chem Int Ed Engl 52:11110–11113CrossRefPubMedGoogle Scholar
  54. 54.
    Coulson EJ (2006) Does p75 neurotrophin receptor mediate Aβ-induced toxicity in Alzheimer’s disease? J Neurochem 98:654–660CrossRefPubMedGoogle Scholar
  55. 55.
    Lue LF, Yan SD, Stern DM, Walker DG (2005) Preventing activation of receptor for advanced glycation end products in Alzheimer’s disease. Curr Drug Targets CNS Neurol Disord 4:249–266CrossRefPubMedGoogle Scholar
  56. 56.
    Sotthibundhu A, Sykes A, Fox B, Underwood CK, Thangnipon W, Coulson EJ (2008) β-Amyloid1–42 induces neuronal death through the p75 neurotrophin receptor. J Neurosci 28:3941–3946CrossRefPubMedGoogle Scholar
  57. 57.
    Murphy M, Wilson YM, Vargas E, Munro KM, Smith B, Huang A, Li QX, Xiao J, Masters CL, Reid CA, Barrett GL (2015) Reduction of p75 neurotrophin receptor ameliorates the cognitive deficits in a model of Alzheimer’s disease. Neurobiol Aging 36:740–752CrossRefPubMedGoogle Scholar
  58. 58.
    Walker D, Lue LF, Paul G, Patel A, Sabbagh MN (2015) Receptor for advanced glycation end product modulators: a new therapeutic target in Alzheimer’s disease expert. Opin Investig Drugs 24:393–399CrossRefGoogle Scholar
  59. 59.
    Gingell JJ, Burns ER, Hay DL (2014) Activity of pramlintide, rat and human amylin but not Aβ1-42 at human amylin receptors. Endocrinology 155:21–26CrossRefPubMedGoogle Scholar
  60. 60.
    Jhamandas JH, MacTavish D (2004) Antagonist of the amylin receptor blocks β-amyloid toxicity in rat cholinergic basal forebrain neurons. J Neurosci 24:5579–5584CrossRefPubMedGoogle Scholar
  61. 61.
    Fu W, Jhamandas JH (2013) Role of amylin and its receptors in neurodegeneration. Curr Protein Pept Sci 14:338–345CrossRefPubMedGoogle Scholar
  62. 62.
    Knowles JK, Rajadas J, Nguyen TV, Yang T, LeMieux MC, Vander Griend L, Ishikawa C, Massa SM, Wyss-Coray T, Longo FM (2009) The p75 neurotrophin receptor promotes amyloid-beta(1-42)-induced neuritic dystrophy in vitro and in vivo. J Neurosci 29:10627–10637CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Sturchler E, Galichet A, Weibel M, Leclerc E, Heizmann CW (2008) Site-specific blockade of RAGE-Vd prevents amyloid-beta oligomer neurotoxicity. J Neurosci 28:5149–5158CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Department of Chemistry and Pharmaceutical ChemistryUniversity of KansasLawrenceUSA
  2. 2.Division of Medical Biochemistry, Department of Biomedical and Biotechnological SciencesUniversity of CataniaCataniaItaly

Personalised recommendations